RenovoRx (RNXT) Fireside Chat summary

Introduction and agenda

• The session featured the CEO and a leading physician discussing commercialization strategy and clinical progress for a novel FDA-cleared drug delivery device targeting pancreatic cancer.

• The agenda included updates on commercialization, clinical trial status, and physician experience, followed by a live Q&A.

Background and experience of the speaker

• The CEO highlighted the company's focus on innovative cancer treatment, leveraging a proprietary device to improve drug delivery and reduce side effects.

• Dr. Tisi shared his experience as an early adopter, emphasizing the device's impact on patient care and its adoption at his institution.

Current industry trends

• There is a shift toward local therapies in cancer treatment, with increasing interest in direct drug delivery to tumors due to limitations of systemic chemotherapy.

• The device's platform is adaptable for future therapies, including immunotherapies and gene-editing treatments.